GRYPHON BIO

Digital Health-Powered Diagnostics & Therapeutics to Accelerate CNS Repair

 

OUR STORY

Gryphon Bio is an early-stage company created to harness our co-founders' discovery of unexpected waves of 1000s of brain molecules in the blood as novel therapeutic targets and temporal central nervous system (CNS) blood biomarkers (brain-specific biomarkers with blood levels that change over time like waves in the ocean). They made these discoveries over more than 19 years of “CNS proteomic” research, the large-scale measurement of proteins in the brain. 

Mission: To develop and market the first digital-health powered diagnostics and therapeutics to accelerate CNS repair.


Vision: To pioneer digital health-powered diagnostics and therapeutics to improve the lives of patients.

 

OUR PIPELINE

Therapeutics

We are developing a promising, diversified pipeline of large molecule medicines, known as biologics, to accelerate CNS repair by following clues from nature’s sequence of cellular and molecular events. Each biologic has a unique mechanism(s) of action (MOA) and pharmacokinetic/pharmacodynamic (PK/PD) profile, compelling biology, and binds to a novel or de-risked therapeutic target(s). 

Digital Health

Virtual clinical trials, where blood specimens and cognitive assessments are collected both in the hospital and at home, guide the development of our temporal CNS blood biomarkers and biologics. In the future, we envision close engagement with our patient communities to assess needs and to develop artificial intelligence-based telemedicine solutions.

Diagnostics

Temporal CNS blood biomarkers can diagnose disease, predict outcome, monitor patients’ disease progression, and phenotype individual trajectories to reconstruct and inform on key decisions. They also improve the likelihood of regulatory approval of our biologics by health authorities. 

 

OUR COURAGEOUS PATIENTS

CNS diseases are leading causes of death and disability, including:

  • Traumatic brain injury (TBI)

  • Multiple sclerosis (MS)

  • Brain metastatic breast cancer (bmBC)

  • Post-traumatic epilepsy (PTE)

  • Alzheimer's disease (AD)

  • Alzheimer's disease-related dementias (ADRD)

  • Chronic traumatic encephalopathy (CTE)

  • Frontotemporal degeneration (FTD)

  • Spinal cord injury (SCI)

  • COVID-19

 

OUR INVESTORS

$7M

Non-Dilutive Funding (Grant Awards)

$130K

Total Cash Raised

 

OUR COURAGEOUS TEAM

We are a proven, cohesive, interdisciplinary and internationally recognized team with deep experience in drug development (e.g., therapeutic bioconjugates), business development (e.g., licensing, intellectual property and partnerships) and CNS biomarker development (e.g., TBI). Together with our advisors, we have 1000+ previous peer-reviewed publications and $100M+ in previous grant awards. Moreover, we have successfully led several preclinical and clinical studies on successful high impact assets in industry and academe.

Will%20Haskins_arctic%20(1)_edited.png

WILL HASKINS, PHD

CEO & Co-Founder

Dr. Willian E. Haskins, Ph.D. (Co-Founder and CEO, GRYPHON BIO, Inc.) in collaboration with Drs. Wang and Forsthuber, discovered unexpected waves of brain molecules in the blood as temporal biomarkers and therapeutic targets. He previously led teams for R&D of gene therapies, therapeutic antibody, and antibody-drug conjugates from Research through Phase I/II/III clinical trials for small and large biotechnology companies, including Genentech. Dr. Haskins is well-respected for developing and applying out-of-the-box solutions to challenging problems. He is highly experienced with analytical and bioanalytical chemistry, proteomics, bioinformatics, CNS biomarkers, and large molecule drug development (OCREVUS®, KADCYLA®, POLIVY®, etc.). He has authored or co-authored more than 73 peer-reviewed publications and numerous patents, and he is the Principal Investigator for several federal grant awards. Lastly, Dr. Haskins completed postdoctoral fellowships at the McKnight Brain Institute and Lawrence Livermore National Laboratories after earning his PhD in Bioanalytical Chemistry from the University of Florida in 2003.

kkw_edited.png

KEVIN WANG, PHD

Co-Founder & Chair of Scientific Advisory Board

Dr. Wang is an Associate Professor of Emergency Medicine and Neuroscience at the University of Florida, leading the Program for Neurotrauma, Neuroproteomics and Biomarker Research. He is an internationally renowned leader for his discovery of temporal biomarker and therapeutic targets for traumatic brain injury (TBI). Dr. Wang pioneered the first tandem, biomarker-based acute TBI blood diagnostic test (i.e., the tandem test) for neuronal ubiquitin C-terminal hydrolase-L1 (UCH-L1) and astrocytic glial fibrillary acidic protein (GFAP). The FDA market-authorized the use of the biomarkers for the tandem test through the De Novo process in 2018. The tandem test fills a gap in the diagnosis of TBI by aiding the identification of brain lesions related to mild TBI or concussion. He holds prominent roles in a number of national and international multi-institutional studies in TBI and related neurological or neurodegenerative diseases. Dr. Wang was previously the Co-Founder and CSO of Banyan Biomarkers and President (current councilor) of the National Neurotrauma Society.

HL_edited.png

HENRY LOWMAN, PHD

Advisor

Dr. Lowman has over 25 years of experience in drug discovery and development, with a focus on biologics. Following an NIH post-doctoral fellowship and scientist career at Genentech, he has held departmental leadership roles in antibody engineering at Genentech and NGM Biopharmaceuticals (NASDAQ: NGM), led the research team as CSO at CytomX Therapeutics (NASDAQ:CTMX), and served as Executive Vice President, Head of R&D at Triphase Accelerator US Corporation, a privately funded drug-development company.

EB_edited_edited.png

ERIC BERNATH

Advisor

Mr. Bernath was formerly a leader in global commercial operations, pricing, and market access at Amgen. Consequently, he is highly experienced with project management for successful drug development.

thumbnail_Gibbs_20100220_3483_edited.png

ANTHONY DELIZZA, MS

Advisor

Tony has 30 years’ experience in biosampling and diagnostic product development, including his leadership role in CLIA laboratory testing services and as a product executive for one of the leading U.S. brands for glucose monitoring.

IMG_4287_edited_edited.png

SWETHA MAHESULA, MS

Research Scientist

A scientific professional with proven experience in leading, designing, and executing preclinical studies for research and development of novel biologics and biomarkers.

If you want to learn more about our amazing team members, get in touch.

 

MEDIA & PRESS UPDATES

What's New

 
FAST_New-Logo_102018-768x210_edited_edited_edited.jpg

GRYPHON BIO SELECTED FOR THE SPRING 2021 CALIFORNIA LIFE SCIENCE INSTITUTE (CLSI) FAST ADVISORY PROGRAM!

Mar 22 2021

GET IN TOUCH

Gryphon Bio, Inc.
611 Gateway Blvd. Suite 120 #253
South San Francisco, CA 94080-7066

  • LinkedIn

Thanks for submitting!